Rixathon 100 mg concentrate for solution for infusion

DRUG6 trials

Sponsors

French Innovative Leukemia Organization, Amsterdam UMC, Alexion Pharmaceuticals Inc., UZ Leuven, Ospedale Pediatrico Bambino Gesu'

Conditions

Complicated forms of idiopathic steroid-sensitive nephrotic syndrome (SSNS)HYPOPHOSPHATASIAPatient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.Patients with previously untreated Richter’s syndrome (RS)Rheumatoid arthritisdefined as the transformation of chronic lymphocytic leukemia (CLL) into high-grade lymphoma of diffuse large B-cell lymphoma (DLBCL) histology.multiple sclerosis

Phase 2

FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY

RecruitingCTIS2022-501554-11-00

French Innovative Leukemia Organizationdefined as the transformation of chronic lymphocytic leukemia (CLL) into high-grade lymphoma of diffuse large B-cell lymphoma (DLBCL) histology., Patients with previously untreated Richter’s syndrome (RS)

Start: 2024-03-21Target: 40Updated: 2025-12-24

The MEMORINEPH study: Memory B cell level-based tailored treatment with Rixathon in children with complicated forms of steroid-sensitive Nephrotic syndrome

WithdrawnCTIS2024-511214-20-00

Ospedale Pediatrico Bambino Gesu'Complicated forms of idiopathic steroid-sensitive nephrotic syndrome (SSNS)

Target: 80Updated: 2024-10-25

TCRaß+CD19+ depleted haploidentical stem cell transplantation followed by immunotherapy in patients with relapsed/resistant high-risk neuroblastoma

RecruitingCTIS2024-519089-32-02

IRCCS Istituto Giannina GasliniPatient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.

Start: 2023-08-29Target: 19Updated: 2025-01-31

Phase 4

Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS

Active, not recruitingCTIS2022-502664-21-00

Amsterdam UMCmultiple sclerosis

Start: 2023-05-01Target: 200Updated: 2025-10-14

Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-Guided Dose Reduction in Patients with Rheumatoid Arthritis: The RITUXERA Trial.

RecruitingCTIS2023-506638-59-01

UZ LeuvenRheumatoid arthritis

Start: 2024-01-09Target: 134Updated: 2025-08-27

An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

CompletedCTIS2022-502793-17-00

Alexion Pharmaceuticals Inc.HYPOPHOSPHATASIA

End: 2025-08-08Target: 1Updated: 2024-09-19

Related Papers

Treat-to-target fixed dose rituximab retreatment versus fixed interval retreatment with disease activity-guided rituximab dose optimisation for patients with rheumatoid arthritis: study protocol for a multicentre randomised controlled superiority trial focusing on long-term disease impact (RITUXERA).

2024-10-151 citations